{"product_id":"hologic-five-forces-analysis","title":"Hologic Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eHologic faces moderate supplier power, strong buyer scrutiny on pricing and clinical outcomes, and intense rivalry from diagnostics and medical-device firms, while regulatory barriers lower but innovation and substitutes pose tangible threats.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Hologic’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Semiconductor and Sensor Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers of specialized semiconductors and sensors for Hologic’s 3Dimensions mammography system exert high bargaining power because fewer than 10 global vendors meet medical-grade specs; component shortages in 2021–23 raised lead times 30–60 days and pushed component costs up ~12% annually. Hologic must secure long-term contracts and dual sourcing to keep its assembly lines supplied and protect FY2024 revenue margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Raw Material Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHologic depends on a small number of global suppliers for reagents and specialty metals used in molecular diagnostics and surgical tools; supplier concentration heightens risk—McKesson-style disruptions can force production slowdowns. In 2024, reagent shortages raised industry assay costs by ~12% and caused 8–15% capacity loss in some labs; concentrated suppliers can push prices during such volatility. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSwitching Costs for Proprietary Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMany components in Hologic diagnostic devices are custom-made to fit its proprietary software and hardware, so switching suppliers would force redesigns and likely FDA re‑certification—costs that can exceed $5–15M per device line based on recent medtech recalls and approvals in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Logistics and Lead Time Constraints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe complexity of Hologic global operations makes suppliers that deliver fast, reliable logistics strategically powerful; in 2024 Hologic reported 18% of revenue tied to kits and consumables that require tight delivery windows, so delays hit sales quickly.\u003c\/p\u003e\n\u003cp\u003eSuppliers with broad distribution networks can charge premiums—logistics providers saw freight rate increases of ~12% in 2023—because timely delivery to hospitals affects patient care and contract compliance.\u003c\/p\u003e\n\u003cp\u003eHologic ability to meet hospital demand depends on upstream efficiency; a 7–10 day lead-time swing in consumables can raise stockout risk and lost revenue during peak flu seasons.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18% revenue exposure to sensitive consumables\u003c\/li\u003e\n\u003cli\u003e12% freight cost rise in 2023\u003c\/li\u003e\n\u003cli\u003e7–10 day lead-time impact on stockouts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Inflation on Input Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpas of late persistent inflation pushed global raw-material prices up year-over-year and us medical-device labor costs letting suppliers pass to manufacturers like hologic rising operating expenses limited substitutes increase their leverage forcing absorb margins or renegotiate longer contracts.\u003e\n\u003cp\u003eHere’s the quick math: a 12% input cost rise on COGS that is 40% of revenue trims gross margin by ~4.8 percentage points unless offset by price or efficiency gains.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12% rise in raw-material prices (2025)\u003c\/li\u003e\n\u003cli\u003e~7% increase in US medical-device labor costs (2025)\u003c\/li\u003e\n\u003cli\u003eCOGS ~40% of revenue → ~4.8 ppt margin hit\u003c\/li\u003e\n\u003cli\u003eSuppliers’ necessity and few substitutes increase bargaining power\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pas\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHologic margins at risk: supplier squeeze, 12% input jump could cut gross margin ~4.8ppt\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold high bargaining power for Hologic due to concentrated, specialized vendors, 2021–25 component\/reagent shortages raising costs ~12% y\/y and 7–10 day lead‑time swings that risk stockouts; COGS ~40% of revenue means a 12% input rise trims gross margin ~4.8 ppt unless offset. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue tied to consumables\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInput price inflation (2025)\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS med‑device labor rise (2025)\u003c\/td\u003e\n\u003ctd\u003e~7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS as % revenue\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross‑margin hit from 12% input rise\u003c\/td\u003e\n\u003ctd\u003e~4.8 ppt\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored Porter’s Five Forces for Hologic, revealing competitive intensity, buyer and supplier leverage, threat of substitutes and new entrants, and strategic levers to protect margins and market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces snapshot for Hologic—distills competitive intensity and strategic levers into one-slide clarity to accelerate board-level decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Healthcare Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe 2024 trend of US hospital mergers raised market share for integrated delivery networks (IDNs) to about 44% of acute care beds, boosting customer bargaining power over suppliers like Hologic.\u003c\/p\u003e\n\u003cp\u003eCentralized procurement lets large IDNs demand deeper volume discounts and extended service contracts, pressuring Hologic’s pricing and margins.\u003c\/p\u003e\n\u003cp\u003eHologic’s margin resilience hinges on proving superior clinical outcomes—studies showing faster diagnosis or lower readmission rates can justify premium pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Group Purchasing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGroup Purchasing Organizations (GPOs) negotiate for over 80% of US hospitals, pushing steep discounts that force Hologic to join GPO formularies to protect share, often lowering per-unit revenue by 10–20% on imaging and diagnostics contracts; in 2024 Hologic reported US product revenue sensitivity to pricing with medical devices facing mid-single-digit margin pressure, so GPO-driven buying makes sales highly competitive and price-sensitive.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShift Toward Value-Based Care Models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs payers and providers shift to value-based care, Hologic must prove products cut total costs by improving outcomes; 2024 studies show tomosynthesis (3D mammography) increases cancer detection by ~20% and can lower downstream treatment costs by an estimated $1,200–$4,500 per patient over five years, so buyers demand ROI evidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice Sensitivity in Molecular Diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eHigh-volume assays drive strong price sensitivity: routine tests let labs compare cost-per-test across platforms, and in 2024 average molecular test reimbursement fell ~3% YoY, increasing margin pressure on Hologic.\u003c\/p\u003e\n\u003cp\u003eCustomers can switch systems if throughput or reagent costs are better elsewhere; global lab consolidation left top 200 labs accounting for ~45% of molecular volumes, boosting buyers’ leverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-volume tests = high price sensitivity\u003c\/li\u003e\n\u003cli\u003e2024 test reimbursement ~ -3% YoY\u003c\/li\u003e\n\u003cli\u003eTop 200 labs = ~45% volume\u003c\/li\u003e\n\u003cli\u003eEasy cost-per-test comparison enables switching\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpectations for Integrated Digital Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eModern healthcare buyers expect Hologic devices to integrate seamlessly with EHRs and AI diagnostics, giving customers leverage to demand built-in interoperability and robust technical support.\u003c\/p\u003e\n\u003cp\u003eThis raises switching costs: Hologic must invest in digital platforms—R\u0026amp;D spending was $340m in FY2024—to meet SLAs and avoid churn, or risk losing contracts to vendors offering open APIs and cloud-native workflows.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math: a 1% churn reduction on Hologic’s ~$4.6bn 2024 revenue equals ~$46m recurring revenue retained.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCustomers demand EHR\/AI integration\u003c\/li\u003e\n\u003cli\u003eHigh support \u0026amp; interoperability required\u003c\/li\u003e\n\u003cli\u003eHologic R\u0026amp;D $340m in FY2024\u003c\/li\u003e\n\u003cli\u003e1% churn cut ≈ $46m revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated Buyers Squeeze Hologic: Reimbursements -3% → 10–20% Discount Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCustomers (IDNs, GPOs, top labs) hold strong bargaining power: IDNs control ~44% acute beds, GPOs cover \u0026gt;80% hospitals, top 200 labs = ~45% molecular volume, and 2024 reimbursement fell ~3% YoY—forcing discounts of 10–20% and pressuring Hologic’s margins despite $340m R\u0026amp;D and $4.6bn 2024 revenue (1% churn ≈ $46m).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIDN acute beds\u003c\/td\u003e\n\u003ctd\u003e~44%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO hospital coverage\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop 200 labs share\u003c\/td\u003e\n\u003ctd\u003e~45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTest reimbursement change\u003c\/td\u003e\n\u003ctd\u003e-3% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHologic R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$340m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHologic revenue\u003c\/td\u003e\n\u003ctd\u003e$4.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiscounts forced\u003c\/td\u003e\n\u003ctd\u003e10–20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eHologic Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Hologic Porter's Five Forces analysis you'll receive immediately after purchase—no surprises or placeholders; it's the full, professionally formatted document ready for download and use.\u003c\/p\u003e\n\u003cp\u003eYou're looking at the actual deliverable: a complete assessment of competitive rivalry, supplier power, buyer power, threat of substitution, and barriers to entry that will be available to you instantly after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747032871289,"sku":"hologic-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/hologic-five-forces-analysis.png?v=1772194445","url":"https:\/\/matrixbcg.com\/products\/hologic-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}